Long believed to be a disease of biblical times, leprosy, also known as Hansen’s disease, continues to be seen in the United States. “Approximately 150 cases are diagnosed each year with 3,000 people in the U.S. currently being treated for leprosy, says James Krahenbuhl, Ph.D., director of the Health Resources Service Administration’s National Hansen’s Disease
Full Post: Leprosy still present in the U.S.
Sun Pharmaceutical Industries Ltd. has announced that its fully owned US subsidiary, Sun Pharmaceutical Industries, Inc., has acquired 100% ownership of Chattem Chemicals, Inc. (Chattem) from Elcat, Inc,.
The terms of the transaction were not disclosed. The Company will apply to regulatory authorities for appropriate clearances, as required.
Chattem is registered with the US Drug Enforcement Administration (DEA) as a narcotic raw material importer. This import registration includes four controlled substance products listed in Schedule 2: methamphetamine, phenylacetone, raw opium and concentrate poppy straw. Additionally, it is also licensed by the DEA to manufacture Schedule 1 to 5 controlled substances. At its facility spread over 6.5 acres in Chattanooga, Tennessee, Chattem employees 60 people and manufactures a variety of active pharmaceutical ingredients (APIs) with a focus on controlled substances. For the year ending June 2008, Chattem is estimated to have sales of USD 26 million.
This is Sun Pharma’s third acquisition of a controlled substance business. In 2005, Sun Pharma acquired a facility in Hungary authorized to make controlled substance APIs, starting from the initial stage, i.e. poppy farming. In the same year, the Company acquired a brand new manufacturing site in New Jersey, equipped with special suites for the manufacture of controlled substances finished dosages.
Dilip Shanghvi, Sun Pharma’s Chairman & Managing Director said, “This acquisition reflects our strategic resolve to be a more active player in the pain management segment in the US.”
http://www.sunpharma.com
--------------------------------------------------------------------------------------------
Related Posts:
Teva Pharmaceutical Industries Ltd. has announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva’s U.S. generic version of AstraZeneca’s Pulmicort (Budesonide) Respules including all claims for patent infringement and damages. Teva launched its generic budesonide respules in the U.S. on November 18, 2008. The
Full Post: Teva announces agreement on generic Pulmicort Respules patent challenge
Sun Pharmaceutical Industries Ltd. announced that together with its subsidiaries, it has received final approval from U.S. FDA for several Abbreviated New Drug Applications (ANDA). Approval was received for generic hydocodone bitartate with acetaminophen (APAP) tablets. Approval was also received for generic Aredia(R), pamidronate disodium for injection USP, generic Lopid (R), gemfibrozil tablets, USP, and
Full Post: Sun Pharmaceutical receives FDA approvals for 4 generics
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva’s acquisition of Barr. In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product
Full Post: Teva and Barr receive European approval for acquisition
Caraco Pharmaceutical Laboratories, Ltd. announced today that it has timely submitted its response to the FDA warning letter that was received on October 31, 2008. In the warning letter, the FDA requested a response from Caraco within 15 business days, ending November 24, 2008. As previously disclosed, the warning letter was issued as a follow
Full Post: Caraco Pharmaceutical Labs responds to FDA warning
SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations. SurModics paid $3 million in cash at closing and may pay up to an additional $6 million in cash upon the
Full Post: SurModics acquires drug delivery assets of PR Pharmaceuticals --------------------------------------------------------------------------------------------
